Intestinal fibrosis in inflammatory bowel disease - Current knowledge and future perspectives

Journal of Crohn's and Colitis

Volumn 2, Issue 4, 2008, Pages 279-290

  Rieder, Florian ^a,b   Fiocchi, Claudio ^b  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Crohn's disease; Extracellular matrix; Fibroblast; Inflammatory bowel disease; Intestinal fibrosis

Indexed keywords

CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; ENTERITIS; FIBROBLAST; INTESTINAL FIBROSIS; PERICYTE; PRIORITY JOURNAL; REVIEW; STELLATE CELL;

EID: 56449084208     PISSN: 18739946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crohns.2008.05.009     Document Type: Review

References (119)

1. Burke J.P., Mulsow J.J., O'Keane C., Docherty N.G., Watson R.W., and O'Connell P.R. Fibrogenesis in Crohn's disease. Am J Gastroenterol 102 (2007) 439-448
2. Van Assche G., Geboes K., and Rutgeerts P. Medical therapy for Crohn's disease strictures. Inflamm Bowel Dis 10 (2004) 55-60
3. Longo W.E., Virgo K.S., Bahadursingh A.N., and Johnson F.E. Patterns of disease and surgical treatment among United States veterans more than 50 years of age with ulcerative colitis. Am J Surg 186 (2003) 514-518
4. Prudhomme M., Dozois R.R., Godlewski G., Mathison S., and Fabbro-Peray P. Anal canal strictures after ileal pouch-anal anastomosis. Dis Colon Rectum 46 (2003) 20-23
5. Farmer R.G., Whelan G., and Fazio V.W. Long-term follow-up of patients with Crohn's disease. Relationship between the clinical pattern and prognosis. Gastroenterology 88 (1985) 1818-1825
6. Silverstein M.D., Loftus E.V., Sandborn W.J., et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology 117 (1999) 49-57
7. Rieder F., Brenmoehl J., Leeb S., Scholmerich J., and Rogler G. Wound healing and fibrosis in intestinal disease. Gut 56 (2007) 130-139
8. Rutgeerts P., Geboes K., Vantrappen G., Beyls J., Kerremans R., and Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology 99 (1990) 956-963
9. Dietz D.W., Laureti S., Strong S.A., et al. Safety and longterm efficacy of strictureplasty in 314 patients with obstructing small bowel Crohn's disease. J Am Coll Surg 192 (2001) 330-337 [discussion 337-338]
10. Louis E., Collard A., Oger A.F., Degroote E., Aboul Nasr El Yafi F.A., and Belaiche J. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 49 (2001) 777-782
11. Cosnes J., Nion-Larmurier I., Beaugerie L., Afchain P., Tiret E., and Gendre J.P. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 54 (2005) 237-241
12. Korzenik J.R., and Podolsky D.K. Evolving knowledge and therapy of inflammatory bowel disease. Nat Rev Drug Discov 5 (2006) 197-209
13. Pucilowska J.B., Williams K.L., and Lund P.K. Fibrogenesis. IV. Fibrosis and inflammatory bowel disease: cellular mediators and animal models. Am J Physiol Gastrointest Liver Physiol 279 (2000) G653-G659
14. Graham M.F. Pathogenesis of intestinal strictures in Crohn's disease - an update. Inflamm Bowel Dis 1 (1995) 220-227
15. Legnani P.E., and Kornbluth A. Therapeutic options in the management of strictures in Crohn's disease. Gastrointest Endosc Clin N Am 12 (2002) 589-603
16. Shen B., Fazio V.W., Remzi F.H., et al. Endoscopic balloon dilation of ileal pouch strictures. Am J Gastroenterol 99 (2004) 2340-2347
17. Morini S., Hassan C., Cerro P., and Lorenzetti R. Management of an ileocolic anastomotic stricture using polyvinyl over-the-guidewire dilators in Crohn's disease. Gastrointest Endosc 53 (2001) 384-386
18. Brooker J.C., Beckett C.G., Saunders B.P., and Benson M.J. Long-acting steroid injection after endoscopic dilation of anastomotic Crohn's strictures may improve the outcome: a retrospective case series. Endoscopy 35 (2003) 333-337
19. Wynn T.A. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 4 (2004) 583-594
20. Powell D.W., Mifflin R.C., Valentich J.D., Crowe S.E., Saada J.I., and West A.B. Myofibroblasts. II. Intestinal subepithelial myofibroblasts. Am J Physiol 277 (1999) C183-C201
21. Hinz B., Phan S.H., Thannickal V.J., Galli A., Bochaton-Piallat M.L., and Gabbiani G. The myofibroblast. One function, multiple origins. Am J Pathol (2007)
22. Smith R.S., Smith T.J., Blieden T.M., and Phipps R.P. Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation. Am J Pathol 151 (1997) 317-322
23. Chang H.Y., Chi J.T., Dudoit S., et al. Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc Natl Acad Sci U S A 99 (2002) 12877-12882
24. Armaka M., Apostolaki M., Jacques P., Kontoyiannis D.L., Elewaut D., and Kollias G. Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases. J Exp Med (2008)
25. Lund P.K., and Zuniga C.C. Intestinal fibrosis in human and experimental inflammatory bowel disease. Curr Opin Gastroenterol 17 (2001) 318-323
26. Lawrance I.C., Maxwell L., and Doe W. Altered response of intestinal mucosal fibroblasts to profibrogenic cytokines in inflammatory bowel disease. Inflamm Bowel Dis 7 (2001) 226-236
27. McKaig B.C., Hughes K., Tighe P.J., and Mahida Y.R. Differential expression of TGF-beta isoforms by normal and inflammatory bowel disease intestinal myofibroblasts. Am J Physiol Cell Physiol 282 (2002) C172-C182
28. Simmons J.G., Pucilowska J.B., Keku T.O., and Lund P.K. IGF-I and TGF-beta1 have distinct effects on phenotype and proliferation of intestinal fibroblasts. Am J Physiol Gastrointest Liver Physiol 283 (2002) G809-G818
29. Theiss A.L., Simmons J.G., Jobin C., and Lund P.K. Tumor necrosis factor (TNF) alpha increases collagen accumulation and proliferation in intestinal myofibroblasts via TNF receptor 2. J Biol Chem 280 (2005) 36099-36109
30. Jobson T.M., Billington C.K., and Hall I.P. Regulation of proliferation of human colonic subepithelial myofibroblasts by mediators important in intestinal inflammation. J Clin Invest 101 (1998) 2650-2657
31. Strutz F., Zeisberg M., Renziehausen A., et al. TGF-beta 1 induces proliferation in human renal fibroblasts via induction of basic fibroblast growth factor (FGF-2). Kidney Int 59 (2001) 579-592
32. Zhao Y., and Young S.L. Requirement of transforming growth factor-beta (TGF-beta) type II receptor for TGF-beta-induced proliferation and growth inhibition. J Biol Chem 271 (1996) 2369-2372
33. Berton A., Levi-Schaffer F., Emonard H., Garbuzenko E., Gillery P., and Maquart F.X. Activation of fibroblasts in collagen lattices by mast cell extract: a model of fibrosis. Clin Exp Allergy 30 (2000) 485-492
34. Gelbmann C.M., Mestermann S., Gross V., Kollinger M., Scholmerich J., and Falk W. Strictures in Crohn's disease are characterised by an accumulation of mast cells colocalised with laminin but not with fibronectin or vitronectin. Gut 45 (1999) 210-217
35. Xu X., Rivkind A., Pikarsky A., Pappo O., Bischoff S.C., and Levi-Schaffer F. Mast cells and eosinophils have a potential profibrogenic role in Crohn disease. Scand J Gastroenterol 39 (2004) 440-447
36. Vogel J.D., West G.A., Danese S., et al. CD40-mediated immune-nonimmune cell interactions induce mucosal fibroblast chemokines leading to T-cell transmigration. Gastroenterology 126 (2004) 63-80
37. Musso A., Condon T.P., West G.A., et al. Regulation of ICAM-1-mediated fibroblast-T cell reciprocal interaction: implications for modulation of gut inflammation. Gastroenterology 117 (1999) 546-556
38. Brown R.D., Jones G.M., Laird R.E., Hudson P., and Long C.S. Cytokines regulate matrix metalloproteinases and migration in cardiac fibroblasts. Biochem Biophys Res Commun 362 (2007) 200-205
39. Sasaki M., Kashima M., Ito T., et al. Differential regulation of metalloproteinase production, proliferation and chemotaxis of human lung fibroblasts by PDGF, interleukin-1beta and TNF-alpha. Mediators Inflamm 9 (2000) 155-160
40. Leeb S.N., Vogl D., Grossmann J., et al. Autocrine fibronectin-induced migration of human colonic myofibroblasts. Am J Gastroenterol 99 (2004) 335-340
41. Leeb S.N., Vogl D., Falk W., Scholmerich J., Rogler G., and Gelbmann C.M. Regulation of migration of human colonic myofibroblasts. Growth Factors 20 (2002) 81-91
42. Leeb S.N., Vogl D., Gunckel M., et al. Reduced migration of fibroblasts in inflammatory bowel disease: role of inflammatory mediators and focal adhesion kinase. Gastroenterology 125 (2003) 1341-1354
43. Suganuma H., Sato A., Tamura R., and Chida K. Enhanced migration of fibroblasts derived from lungs with fibrotic lesions. Thorax 50 (1995) 984-989
44. Pontz B.F., Albini A., Mensing H., Cantz M., and Muller P.K. Pattern of collagen synthesis and chemotactic response of fibroblasts derived from mucopolysaccharidosis patients. Exp Cell Res 155 (1984) 457-466
45. Brouty-Boye D., Cheng Y.S., and Chen L.B. Association of phenotypic reversion of transformed cells induced by interferon with morphological and biochemical changes in the cytoskeleton. Cancer Res 41 (1981) 4174-4184
46. Knittel T., Kobold D., Saile B., et al. Rat liver myofibroblasts and hepatic stellate cells: different cell populations of the fibroblast lineage with fibrogenic potential. Gastroenterology 117 (1999) 1205-1221
47. Apte M.V., Haber P.S., Darby S.J., et al. Pancreatic stellate cells are activated by proinflammatory cytokines: implications for pancreatic fibrogenesis. Gut 44 (1999) 534-541
48. Matsuura T., Hasumura S., Nagamori S., and Murakami K. Retinol esterification activity contributes to retinol transport in stellate cells. Cell Struct Funct 24 (1999) 111-116
49. Rockey D.C. Hepatic fibrosis, stellate cells, and portal hypertension. Clin Liver Dis 10 (2006) 459-479 [vii-viii]
50. Nagy N.E., Holven K.B., Roos N., et al. Storage of vitamin A in extrahepatic stellate cells in normal rats. J Lipid Res 38 (1997) 645-658
51. Theise N.D., Badve S., Saxena R., et al. Derivation of hepatocytes from bone marrow cells in mice after radiation-induced myeloablation. Hepatology 31 (2000) 235-240
52. Lagaaij E.L., Cramer-Knijnenburg G.F., van Kemenade F.J., van Es L.A., Bruijn J.A., and van Krieken J.H. Endothelial cell chimerism after renal transplantation and vascular rejection. Lancet 357 (2001) 33-37
53. Orlic D., Kajstura J., Chimenti S., et al. Bone marrow cells regenerate infarcted myocardium. Nature 410 (2001) 701-705
54. Poulsom R., Forbes S.J., Hodivala-Dilke K., et al. Bone marrow contributes to renal parenchymal turnover and regeneration. J Pathol 195 (2001) 229-235
55. Brittan M., and Wright N.A. Gastrointestinal stem cells. J Pathol 197 (2002) 492-509
56. Brittan M., Chance V., Elia G., et al. A regenerative role for bone marrow following experimental colitis: contribution to neovasculogenesis and myofibroblasts. Gastroenterology 128 (2005) 1984-1995
57. Bamba S., Lee C.Y., Brittan M., et al. Bone marrow transplantation ameliorates pathology in interleukin-10 knockout colitic mice. J Pathol 209 (2006) 265-273
58. Direkze N.C., Jeffery R., Hodivala-Dilke K., et al. Bone marrow-derived stromal cells express lineage-related messenger RNA species. Cancer Res 66 (2006) 1265-1269
59. Khalil P.N., Weiler V., Nelson P.J., et al. Nonmyeloablative stem cell therapy enhances microcirculation and tissue regeneration in murine inflammatory bowel disease. Gastroenterology 132 (2007) 944-954
60. Lamagna C., and Bergers G. The bone marrow constitutes a reservoir of pericyte progenitors. J Leukoc Biol 80 (2006) 677-681
61. Kalluri R., and Neilson E.G. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 112 (2003) 1776-1784
62. Lee J.M., Dedhar S., Kalluri R., and Thompson E.W. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 172 (2006) 973-981
63. Bates R.C., and Mercurio A.M. Tumor necrosis factor-alpha stimulates the epithelial-to-mesenchymal transition of human colonic organoids. Mol Biol Cell 14 (2003) 1790-1800
64. Strutz F., Zeisberg M., Ziyadeh F.N., et al. Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation. Kidney Int 61 (2002) 1714-1728
65. Zhang A., Jia Z., Guo X., and Yang T. Aldosterone induces epithelial-mesenchymal transition via ROS of mitochondrial origin. Am J Physiol Renal Physiol 293 (2007) F723-F731
66. Zeisberg M., Hanai J., Sugimoto H., et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 9 (2003) 964-968
67. Zeisberg M., Yang C., Martino M., et al. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem 282 (2007) 23337-23347
68. Kaimori A., Potter J., Kaimori J.Y., Wang C., Mezey E., and Koteish A. Transforming growth factor-beta1 induces an epithelial-to-mesenchymal transition state in mouse hepatocytes in vitro. J Biol Chem 282 (2007) 22089-22101
69. Yang J., Dai C., and Liu Y. A novel mechanism by which hepatocyte growth factor blocks tubular epithelial to mesenchymal transition. J Am Sco Nephrol 16 (2005) 68-78
70. Kagawa T., Takemura G., Kosai K., et al. Hepatocyte growth factor gene therapy slows down the progression of diabetic nephropathy in db/db mice. Nephron Physiol 102 (2006) 92-102
71. Kim W.H., Matsumoto K., Bessho K., and Nakamura T. Growth inhibition and apoptosis in liver myofibroblasts promoted by hepatocyte growth factor leads to resolution from liver cirrhosis. Am J Pathol 166 (2005) 1017-1028
72. Yamashita J., Itoh H., Hirashima M., et al. Flk1-positive cells derived from embryonic stem cells serve as vascular progenitors. Nature 408 (2000) 92-96
73. Frid M.G., Kale V.A., and Stenmark K.R. Mature vascular endothelium can give rise to smooth muscle cells via endothelial-mesenchymal transdifferentiation: in vitro analysis. Circ Res 90 (2002) 1189-1196
74. Sarkisov D.S., Kolokol'chikova E.G., Kaem R.I., and Pal'tsyn A.A. Vascular changes in maturing granulation tissue. Biull Eksp Biol Med 105 (1988) 501-503
75. Romero L.I., Zhang D.N., Herron G.S., and Karasek M.A. Interleukin-1 induces major phenotypic changes in human skin microvascular endothelial cells. J Cell Physiol 173 (1997) 84-92
76. Chaudhuri V., Zhou L., and Karasek M. Inflammatory cytokines induce the transformation of human dermal microvascular endothelial cells into myofibroblasts: a potential role in skin fibrogenesis. J Cutan Pathol 34 (2007) 146-153
77. Zeisberg E.M., Tarnavski O., Zeisberg M., et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 13 (2007) 952-961
78. Arciniegas E., Sutton A.B., Allen T.D., and Schor A.M. Transforming growth factor beta 1 promotes the differentiation of endothelial cells into smooth muscle-like cells in vitro. J Cell Sci 103 Pt 2 (1992) 521-529
79. Arciniegas E., Neves Y.C., and Carrillo L.M. Potential role for insulin-like growth factor II and vitronectin in the endothelial-mesenchymal transition process. Differentiation 74 (2006) 277-292
80. Wilm B., Ipenberg A., Hastie N.D., Burch J.B., and Bader D.M. The serosal mesothelium is a major source of smooth muscle cells of the gut vasculature. Development 132 (2005) 5317-5328
81. Allt G., and Lawrenson J.G. Pericytes: cell biology and pathology. Cells Tissues Organs 169 (2001) 1-11
82. Helmbold P., Nayak R.C., Marsch W.C., and Herman I.M. Isolation and in vitro characterization of human dermal microvascular pericytes. Microvasc Res 61 (2001) 160-165
83. von Tell D., Armulik A., and Betsholtz C. Pericytes and vascular stability. Exp Cell Res 312 (2006) 623-629
84. Gerhardt H., and Betsholtz C. Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res 314 (2003) 15-23
85. Sundberg C., Ivarsson M., Gerdin B., and Rubin K. Pericytes as collagen-producing cells in excessive dermal scarring. Lab Invest 74 (1996) 452-466
86. Kahari V.M., Sandberg M., Kalimo H., Vuorio T., and Vuorio E. Identification of fibroblasts responsible for increased collagen production in localized scleroderma by in situ hybridization. J Invest Dermatol 90 (1988) 664-670
87. Maher J.J., and McGuire R.F. Extracellular matrix gene expression increases preferentially in rat lipocytes and sinusoidal endothelial cells during hepatic fibrosis in vivo. J Clin Invest 86 (1990) 1641-1648
88. Arihiro S., Ohtani H., Hiwatashi N., Torii A., Sorsa T., and Nagura H. Vascular smooth muscle cells and pericytes express MMP-1, MMP-9, TIMP-1 and type I procollagen in inflammatory bowel disease. Histopathology 39 (2001) 50-59
89. Bagley R.G., Rouleau C., Morgenbesser S.D., et al. Pericytes from human non-small cell lung carcinomas: an attractive target for anti-angiogenic therapy. Microvasc Res 71 (2006) 163-174
90. Sennino B., Falcon B.L., McCauley D., et al. Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102. Cancer Res 67 (2007) 7358-7367
91. Bellini A., and Mattoli S. The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. Lab Invest 87 (2007) 858-870
92. Quan T.E., Cowper S., Wu S.P., Bockenstedt L.K., and Bucala R. Circulating fibrocytes: collagen-secreting cells of the peripheral blood. Int J Biochem Cell Biol 36 (2004) 598-606
93. Bucala R., Spiegel L.A., Chesney J., Hogan M., and Cerami A. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med 1 (1994) 71-81
94. Gordon S., and Taylor P.R. Monocyte and macrophage heterogeneity. Nat Rev Immunol 5 (2005) 953-964
95. Zhao Y., Glesne D., and Huberman E. A human peripheral blood monocyte-derived subset acts as pluripotent stem cells. Proc Natl Acad Sci U S A 100 (2003) 2426-2431
96. Kuwana M., Okazaki Y., Kodama H., et al. Human circulating CD14+ monocytes as a source of progenitors that exhibit mesenchymal cell differentiation. J Leukoc Biol 74 (2003) 833-845
97. Schmidt M., Sun G., Stacey M.A., Mori L., and Mattoli S. Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma. J Immunol 171 (2003) 380-389
98. Abe R., Donnelly S.C., Peng T., Bucala R., and Metz C.N. Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J Immunol 166 (2001) 7556-7562
99. Pilling D., Tucker N.M., and Gomer R.H. Aggregated IgG inhibits the differentiation of human fibrocytes. J Leukoc Biol 79 (2006) 1242-1251
100. Pilling D., Buckley C.D., Salmon M., and Gomer R.H. Inhibition of fibrocyte differentiation by serum amyloid P. J Immunol 171 (2003) 5537-5546
101. Haudek S.B., Xia Y., Huebener P., et al. Bone marrow-derived fibroblast precursors mediate ischemic cardiomyopathy in mice. Proc Natl Acad Sci U S A 103 (2006) 18284-18289
102. Varcoe R.L., Mikhail M., Guiffre A.K., et al. The role of the fibrocyte in intimal hyperplasia. J Thromb Haemost 4 (2006) 1125-1133
103. Sakai N., Wada T., Yokoyama H., et al. Secondary lymphoid tissue chemokine (SLC/CCL21)/CCR7 signaling regulates fibrocytes in renal fibrosis. Proc Natl Acad Sci U S A 103 (2006) 14098-14103
104. Aiba S., and Tagami H. Inverse correlation between CD34 expression and proline-4-hydroxylase immunoreactivity on spindle cells noted in hypertrophic scars and keloids. J Cutan Pathol 24 (1997) 65-69
105. Cowper S.E., Su L.D., Bhawan J., Robin H.S., and LeBoit P.E. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 23 (2001) 383-393
106. Postlethwaite A.E., Shigemitsu H., and Kanangat S. Cellular origins of fibroblasts: possible implications for organ fibrosis in systemic sclerosis. Curr Opin Rheumatol 16 (2004) 733-738
107. Nimphius W., Moll R., Olbert P., Ramaswamy A., and Barth P.J. CD34+ fibrocytes in chronic cystitis and noninvasive and invasive urothelial carcinomas of the urinary bladder. Virchows Arch 450 (2007) 179-185
108. Barth P.J., Ebrahimsade S., Hellinger A., Moll R., and Ramaswamy A. CD34+ fibrocytes in neoplastic and inflammatory pancreatic lesions. Virchows Arch 440 (2002) 128-133
109. Chauhan H., Abraham A., Phillips J.R., Pringle J.H., Walker R.A., and Jones J.L. There is more than one kind of myofibroblast: analysis of CD34 expression in benign, in situ, and invasive breast lesions. J Clin Pathol 56 (2003) 271-276
110. Sorrentino D., Avellini C., Beltrami C.A., Pasqual E., and Zearo E. Selective effect of infliximab on the inflammatory component of a colonic stricture in Crohn's disease. Int J Colorectal Dis 21 (2006) 276-281
111. Sorrentino D., Terrosu G., Vadala S., and Avellini C. Fibrotic strictures and anti-TNF-alpha therapy in Crohn's disease. Digestion 75 (2007) 22-24
112. Lichtenstein G.R., Olson A., Travers S., et al. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol 101 (2006) 1030-1038
113. Swaminath A., and Lichtiger S. Dilation of colonic strictures by intralesional injection of infliximab in patients with Crohn's colitis. Inflamm Bowel Dis 14 (2008) 213-216
114. Van Assche G. Intramural steroid injection and endoscopic dilation for Crohn's disease. Clin Gastroenterol Hepatol 5 (2007) 1027-1028
115. Kugathasan S., Collins N., Maresso K., et al. CARD15 gene mutations and risk for early surgery in pediatric-onset Crohn's disease. Clin Gastroenterol Hepatol 2 (2004) 1003-1009
116. Pilling D., Roife D., Wang M., et al. Reduction of bleomycin-induced pulmonary fibrosis by serum amyloid P. J Immunol 179 (2007) 4035-4044
117. Kelly D.J., Zhang Y., Gow R., and Gilbert R.E. Tranilast attenuates structural and functional aspects of renal injury in the remnant kidney model. J Am Soc Nephrol 15 (2004) 2619-2629
118. Martin J., Kelly D.J., Mifsud S.A., et al. Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-beta. Cardiovasc Res 65 (2005) 694-701
119. Oshitani N., Yamagami H., Watanabe K., Higuchi K., and Arakawa T. Long-term prospective pilot study with tranilast for the prevention of stricture progression in patients with Crohn's disease. Gut 56 (2007) 599-600